Aristea Therapeutics Announces Dosing of First Patient in Open-Label Extension for Phase 2b Trial of RIST4721 in Palmoplantar Pustulosis
Excerpt from the Press Release:
SAN DIEGO, June 30, 2022 /PRNewswire/ — Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat serious inflammatory diseases, today announced it has dosed its first subject in the open-label extension (OLE) for its Phase 2b trial of RIST4721 in palmoplantar pustulosis (PPP), a rare dermatological condition.
“This brings us another step forward in the development of a potential treatment for this burdensome disease,” commented James M. Mackay, Ph.D., President and CEO of Aristea. “PPP has no approved therapies in the US or Europe and there is a significant unmet medical need for these patients. The OLE of our Phase 2b clinical trial will allow us to collect additional long-term safety and efficacy data that will help us further characterize the potential for RIST4721 in patients with PPP”
PPP is is characterized by the recurrent appearance of sterile pustules filled with neutrophils on the palms of the hands and soles of the feet. It poses dramatic challenges to quality of life and the performance of daily tasks for patients suffering from PPP.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?